Opinion|Videos|November 17, 2025
EDGE-Gastric Trial: Breaking Down Data for Domvanalimab/Zimberelimab Plus Chemo in First-Line Gastric/GEJ/Esophageal Adenocarcinoma
Author(s)Yelena Y. Janjigian, MD, Zev A. Wainberg, MD
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.
Advertisement
Episodes in this series
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, dissect the results from arm A1 of the phase 2 EDGE-Gastric trial evaluating domvanalimab plus zimberelimab and FOLFOX in first-line advanced gastric, GEJ, and esophageal adenocarcinoma. They outline key efficacy signals, including durability of response, and progression-free survival trends, while also commenting on the safety profile and any emerging toxicities observed with longer follow-up. They explain how these findings further strengthen the clinical rationale for this dual-checkpoint strategy in the frontline setting.
Advertisement
Related to this article
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery
Ruxolitinib 1.5% cream outperformed placebo vehicle in reducing lesional skin involvement in patients with epidermal or superficially sclerotic cutaneous chronic GVHD.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
3
Talquetamab Demonstrates Preserved Activity in MonumenTAL-1–Ineligible Patients With Relapsed/Refractory Myeloma
4
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
5